CG Oncology (CGON) Other Non-Current Liabilities (2023 - 2026)
CG Oncology posted quarterly Other Non-Current Liabilities of $1.5 million for Q1 2026, down 16.66% on a QoQ basis from $1.7 million in Q4 2025.
CG Oncology (CGON) has 3 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (changed N/A YoY), and the FY2025 full-year result was $1.7 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.5 million, down from $1.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.8 million in Q3 2025 and bottomed at $365000.0 in Q4 2023.
- The 3-year median for Other Non-Current Liabilities is $1.6 million (2025), against an average of $1.8 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Dec 31, 2023 | 365,000.00 |